Cumulated Activity Comparison of <sup>64</sup>Cu-/<sup>177</sup>Lu-Labeled Anti-Epidermal Growth Factor Receptor Antibody in Esophageal Squamous Cell Carcinoma Model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28082435.
- Also identified by DOI 10.2967/jnumed.116.180521.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This work aimed at estimating the kinetic parameters, and hence cumulated activity (A<sub>C</sub>), of a diagnostic/therapeutic convergence radiopharmaceutical, namely <sup>64</sup>Cu-/<sup>177</sup>Lu-labeled antibody (<sup>64</sup>Cu-/<sup>177</sup>Lu-cetuximab), that acts as anti-epidermal growth factor receptor. <b>Methods:</b> In mice bearing esophageal squamous cell carcinoma tumors, to estimate uptake (K), release rate constant (k<sub>R</sub>), and hence A<sub>C</sub>, a kinetic model analysis was applied to recently published biodistribution data of immuno-PET imaging with <sup>64</sup>Cu-cetuximab and of small-animal SPECT/CT imaging with <sup>177</sup>Lu-cetuximab, including blood and TE-8 tumor. <b>Results:</b> K, k<sub>R</sub>, and A<sub>C</sub> were estimated to be 0.0566/0.0593 g⋅h<sup>-1</sup>⋅g<sup>-1</sup>, 0.0150/0.0030 h<sup>-1</sup>, and 2.3 × 10<sup>10</sup>/4.1 × 10<sup>12</sup> disintegrations (per gram of TE-8 tumor), with an injected activity of 3.70/12.95 MBq, for <sup>64</sup>Cu-/<sup>177</sup>Lu-cetuximab, respectively. <b>Conclusion:</b> A model is available for comparing kinetic parameters and A<sub>C</sub> of the companion diagnostic/therapeutic <sup>64</sup>Cu-/<sup>177</sup>Lu-cetuximab that may be considered as a step for determining whether one can really use the former to predict dosimetry of the latter.
Medical subject headings
- Antibodies, Monoclonal
- Carcinoma, Squamous Cell
- Copper Radioisotopes
- ErbB Receptors
- Esophageal Neoplasms
- Lutetium